OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Recommendation of “Buy” by Analysts

Posted by Defense World Staff on May 15th, 2023

OrthoPediatrics Corp. (NASDAQ:KIDS – Get Rating) has received a consensus recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $55.33.

A number of analysts have issued reports on KIDS shares. Truist Financial lifted their target price on shares of OrthoPediatrics from $53.00 to $57.00 and gave the company a “buy” rating in a research note on Monday, April 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $51.00 target price on shares of OrthoPediatrics in a research report on Monday, April 17th. TheStreet lowered shares of OrthoPediatrics from a “c” rating to a “d+” rating in a report on Wednesday, March 1st. Finally, 1-800-FLOWERS.COM reaffirmed a “maintains” rating on shares of OrthoPediatrics in a report on Tuesday, May 2nd.

Insider Activity at OrthoPediatrics

In related news, General Counsel Daniel J. Gerritzen sold 3,315 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $44.62, for a total value of $147,915.30. Following the sale, the general counsel now directly owns 35,527 shares in the company, valued at approximately $1,585,214.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Mark C. Throdahl sold 4,515 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $43.83, for a total value of $197,892.45. Following the completion of the transaction, the director now directly owns 128,024 shares of the company’s stock, valued at $5,611,291.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Daniel J. Gerritzen sold 3,315 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $44.62, for a total transaction of $147,915.30. Following the completion of the transaction, the general counsel now directly owns 35,527 shares of the company’s stock, valued at $1,585,214.74. The disclosure for this sale can be found here. Insiders have sold 26,761 shares of company stock worth $1,208,081 in the last ninety days. Company insiders own 29.50% of the company’s stock.

Institutional Investors Weigh In On OrthoPediatrics

Several hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors LP lifted its holdings in shares of OrthoPediatrics by 1.3% during the first quarter. Wasatch Advisors LP now owns 391,311 shares of the company’s stock worth $17,331,000 after buying an additional 5,176 shares in the last quarter. BNP Paribas Arbitrage SNC lifted its stake in shares of OrthoPediatrics by 147.4% in the first quarter. BNP Paribas Arbitrage SNC now owns 4,273 shares of the company’s stock worth $189,000 after acquiring an additional 2,546 shares during the period. Bank of America Corp DE lifted its stake in shares of OrthoPediatrics by 37.0% in the first quarter. Bank of America Corp DE now owns 87,410 shares of the company’s stock worth $3,871,000 after acquiring an additional 23,599 shares during the period. UBS Group AG lifted its stake in OrthoPediatrics by 36.4% in the first quarter. UBS Group AG now owns 9,544 shares of the company’s stock valued at $423,000 after buying an additional 2,549 shares during the period. Finally, Next Century Growth Investors LLC lifted its stake in OrthoPediatrics by 8.1% in the first quarter. Next Century Growth Investors LLC now owns 604,275 shares of the company’s stock valued at $26,763,000 after buying an additional 45,053 shares during the period. Institutional investors and hedge funds own 97.02% of the company’s stock.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $45.19 on Monday. The firm’s 50 day simple moving average is $45.45 and its 200-day simple moving average is $43.76. The company has a market cap of $1.05 billion, a P/E ratio of 225.95 and a beta of 0.89. OrthoPediatrics has a fifty-two week low of $35.67 and a fifty-two week high of $60.75.

OrthoPediatrics (NASDAQ:KIDS – Get Rating) last released its earnings results on Tuesday, February 28th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.10). The firm had revenue of $30.99 million during the quarter, compared to analysts’ expectations of $31.01 million. OrthoPediatrics had a negative return on equity of 5.32% and a net margin of 2.72%. On average, analysts expect that OrthoPediatrics will post -0.94 EPS for the current fiscal year.

OrthoPediatrics Company Profile

(Get Rating)

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A.